Literature DB >> 1548782

Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates.

K Schlienger1, M Mancini, Y Rivière, D Dormont, P Tiollais, M L Michel.   

Abstract

Hepatitis B surface antigen (HBsAg) produced by recombinant DNA technology is now widely and safely used worldwide for hepatitis B vaccination. We used the HBsAg particle as a carrier molecule for presentation of selected human immunodeficiency virus type 1 (HIV-1) determinants to the immune system. Immunization of rhesus monkeys with an HBsAg chimera carrying the HIV-1 envelope major neutralizing determinant allowed us to generate proliferative T-cell responses and, in some cases, neutralizing antibodies and antibody-dependent cellular cytotoxicity. Since there is an overlap between populations at risk for hepatitis B virus and HIV, HBsAg recombinant particles may be relevant carriers for HIV-1 epitopes and could offer a new approach to the development of an AIDS vaccine.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1548782      PMCID： PMC289060     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  31 in total

1.  A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.

Authors:  P A Broliden; K Ljunggren; J Hinkula; E Norrby; L Akerblom; B Wahren
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

2.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.

Authors:  K Deres; H Schild; K H Wiesmüller; G Jung; H G Rammensee
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

3.  Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.

Authors:  J S McDougal; J K Nicholson; G D Cross; S P Cort; M S Kennedy; A C Mawle
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

4.  Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles.

Authors:  M L Michel; M Mancini; E Sobczak; V Favier; D Guetard; E M Bahraoui; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

5.  Vaccine protection against simian immunodeficiency virus infection.

Authors:  R C Desrosiers; M S Wyand; T Kodama; D J Ringler; L O Arthur; P K Sehgal; N L Letvin; N W King; M D Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

6.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.

Authors:  P S Linsley; J A Ledbetter; E Kinney-Thomas; S L Hu
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

8.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

Authors:  S D Putney; T J Matthews; W G Robey; D L Lynn; M Robert-Guroff; W T Mueller; A J Langlois; J Ghrayeb; S R Petteway; K J Weinhold
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

10.  Human T cell response to the surface antigen of hepatitis B virus (HBsAg). Endosomal and nonendosomal processing pathways are accessible to both endogenous and exogenous antigen.

Authors:  Y Jin; W K Shih; I Berkower
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307
View more
  12 in total

Review 1.  Virus-like particles production in green plants.

Authors:  Luca Santi; Zhong Huang; Hugh Mason
Journal:  Methods       Date:  2006-09       Impact factor: 3.608

2.  Proposition of a three-dimensional representation of the constitutive protein of the hepatitis B surface antigen particles.

Authors:  N Sonveaux; J M Ruysschaert; R Brasseur
Journal:  J Protein Chem       Date:  1995-08

3.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.

Authors:  J C Griffiths; S J Harris; G T Layton; E L Berrie; T J French; N R Burns; S E Adams; A J Kingsman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

4.  Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen.

Authors:  Natasha Larke; Aileen Murphy; Christoph Wirblich; Denise Teoh; Marie J Estcourt; Andrew J McMichael; Polly Roy; Tomás Hanke
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 5.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

6.  Incorporation of pseudorabies virus gD into human immunodeficiency virus type 1 Gag particles produced in baculovirus-infected cells.

Authors:  L Garnier; M Ravallec; P Blanchard; H Chaabihi; J P Bossy; G Devauchelle; A Jestin; M Cerutti
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques.

Authors:  Deborah Heydenburg Fuller; Tim Shipley; Todd M Allen; James T Fuller; Mary S Wu; Helen Horton; Nancy Wilson; Georg Widera; David I Watkins
Journal:  Virology       Date:  2007-04-11       Impact factor: 3.616

8.  Antigen targeting to antigen-presenting cells enhances presentation to class II-restricted T lymphocytes.

Authors:  A Scardino; M Paroli; G De Petrillo; M L Michel; V Barnaba
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

9.  Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.

Authors:  K Schlienger; D C Montefiori; M Mancini; Y Rivière; P Tiollais; M L Michel
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

Review 10.  Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.

Authors:  Joan Kha-Tu Ho; Beena Jeevan-Raj; Hans-Jürgen Netter
Journal:  Viruses       Date:  2020-01-21       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.